U.S. medical device maker Boston Scientific Corp has agreed to buy Britain’s BTG Plc for 3.3 billion pounds ($4.24 billion) in cash, adding technology to fight cancer and other serious diseases to its portfolio.
Boston Scientific – best known for making stents to prop open clogged heart arteries – has agreed to pay 840 pence per share, representing a premium of 36.6 percent to BTG’s previous closing price, the companies said on Tuesday.
Shares of BTG soared by a third to 825p by 1200 GMT after touching 832p, their highest level since Jan. 2015. Up to Monday’s close, they had slipped 19.3 percent this year, despite jumping last week on strong first-half results.
Boston Scientific said BTG’s interventional medicine products, which use devices to deliver drugs to affected organs, would augment its capabilities in important areas of unmet need such as cancer and pulmonary embolism.
BTG, which has long produced drugs to treat overdoses and rattlesnake bites, has focused on interventional medicine in recent years, for example producing beads that target tumors.
Boston Scientific’s Chairman and CEO Michael Mahoney said the addition of BTG’s therapies would ultimately advance patient care in ways that could not be realized by either company alone, while also providing a strong return for investors.
BTG said it considered the terms of the offer to be fair and reasonable and it planned to recommend the deal to shareholders.
Industry experts agreed the offer looked reasonable and Jefferies analyst Peter Welford said BTG’s eclectic product mix made a counterbid unlikely, despite past competition for interventional oncology products.
Australia’s Sirtex, which also makes tumor-targeting beads, was eventually acquired by China-based CDH Investments in June, following an initial bid from Varian.
Boston Scientific said buying BTG was expected to boost adjusted earnings by 2 to 3 cents a share in 2019 and would be increasingly accretive thereafter.
The deal is Boston Scientific’s biggest since its 2006 acquisition of heart device maker Guidant Corp for $27 billion, which left the company laden with debt and dealing with a slew of Guidant product recalls.
For BTG, the sale marks the end of the independence of an organization that traces its roots back to Britain’s National Research Development Corporation, founded by the government in 1948 to commercialize publicly funded research.
BTG was privatized in 1992 and listed on the London Stock Exchange three years later.
Barclays advised Boston Scientific, while BTG was advised by Goldman Sachs, J.P. Morgan and Rothschild. ($1 = 0.7786 pounds)
By Paul Sandle, Ben Hirschler and Shashwat Awasthi
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.